MediXall Group (NASDAQ: MDXL) notifies SEC of late 10-Ks and 10-Qs
Filing Impact
Filing Sentiment
Form Type
NT 10-Q
Rhea-AI Filing Summary
MediXall Group, Inc. submitted a Form 12b-25 notification dated May 15, 2026 reporting a late filing for the period ended March 31, 2026. The company cites that "certain financial and other information" could not be provided without "unreasonable effort or expense." The filing states the company is delinquent in its 2024 Form 10-K, the Form 10-Qs for the quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, and the 2025 Form 10-K, and that it is preparing those reports for submission.
Positive
- None.
Negative
- None.
Key Figures
Form type: Form 12b-25
Period ended: March 31, 2026
Notification date: May 15, 2026
+2 more
5 metrics
Form type
Form 12b-25
Notification of late filing
Period ended
March 31, 2026
Period referenced on the Form 12b-25 cover
Notification date
May 15, 2026
Date the notification was signed by CFO Travis Jackson
Delinquent filings listed
2024 Form 10-K; 2025 Form 10-K; three 10-Qs
Specifically: Qs ended March 31, June 30, and Sept 30, 2025
Contact phone
800-381-1787
Contact for notification: Travis Jackson, CFO
Key Terms
Rule 12b-25, Form 12b-25, Delinquent periodic reports
3 terms
Rule 12b-25 regulatory
""PART II 12b-25(b) and (c)" notification language"
Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.
Form 12b-25 regulatory
""NOTIFICATION OF LATE FILING" cover line"
Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.
Delinquent periodic reports regulatory
""The Company is delinquent in filing the 2024 Form 10-K""
FAQ
What did MediXall Group (MDXL) file with the SEC?
MediXall filed a Form 12b-25 notification dated May 15, 2026. The filing states certain required periodic reports could not be completed without "unreasonable effort or expense," and lists multiple delinquent 10-K and 10-Q filings the company is preparing to submit.
Which periodic reports is MDXL delinquent in filing?
The company reports delinquency in the 2024 Form 10-K, the Form 10-Qs for quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, and the 2025 Form 10-K. The notice states these reports are being prepared for filing with the SEC.
Does the 12b-25 state whether reported earnings will change materially?
The notice answers that no significant change in results of operations is anticipated; the company checked "No" to anticipated significant changes versus the prior year. No quantitative earnings estimates or details are provided in the excerpt.
Who is the contact for the filing and how can they be reached?
The contact listed is Travis Jackson, Chief Financial Officer. The telephone number provided in the notification is 800-381-1787. This contact is named for inquiries regarding the late-filing notification.
What reason does MDXL give for the late filings?
The company states that "certain financial and other information necessary for an accurate and full completion of the Report could not be provided within the prescribed time period without unreasonable effort or expense." No further specifics are included in the excerpt.